P3.01-33 EGFR Mutation in Patients With NSCLC and Its Relationship Between Survival and Clinicopathological Features: An Update Analysis

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1593
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P3.01-75 RELAY+, an Exploratory Study of Gefitinib With Ramucirumab in Untreated Patients With EGFR Mutation-Positive Metastatic NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-84 the Association of CDKN2A Gene Mutation With Clinicopathological Features and Prognosis in Advanced Lung Cancer Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA07.05 Local Ablative Therapy Improves Survival in Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated With EGFR-TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.09-04 PD-L1 Expression in Primary Lung Adenocarcinoma and Its Relation With EGFR / KRAS Mutation and Clinicopathological Features

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-12 EGFR Mutation and Targeted Therapies: Difficulties and Disparities in Access to NSCLC Treatment in Brazil

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P010 Relationship Between EGFR and KRAS Mutation and the Clinicopathologic Features of Early Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Relationship Between EGFR Mutation and Computed Tomography Characteristics of the Lung in Patients With Lung Adenocarcinoma

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy